Prevalence of metabolic syndrome among patients with schizophrenia in Japan

Sugawara, Norio; Yasui‐Furukori, Norio; Sato, Yasushi; Umeda, Takashi; Kishida, Ikuko; Yamashita, Hakuei; Saito, Manabu; Furukori, Hanako; Nakagami, Taku; Hatakeyama, Mitsunori; Nakaji, Shigeyuki; Kaneko, Sunao

doi:10.1016/j.schres.2010.08.030

Cited by 76 publications

(82 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to the IDF, the prevalence of MetS in Japanese schizophrenia patients is 25.4% [Sugawara et al 2010], and is 17.0% in Japanese male workers [Miyaki et al 2006]. In our study, a high prevalence of MetS were found in schizophrenic patients (34.9% even after 2-years' study).…”

Section: Discussionsupporting

confidence: 50%

Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics

Kawabe

Ochi

Yoshino

et al. 2015

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

Background: Common adverse effects of atypical antipsychotic treatments for schizophrenia are weight gain and lipid metabolism abnormality. We aimed to identify the signs of metabolic problems with continuous atypical antipsychotic treatment for schizophrenia over a 2-year period. Methods: The participants were 68 schizophrenic patients (29 males, 39 females; ages 53.4 ± 13.5 years old). Changes in carbohydrate metabolism and changes in physical characteristics were studied over a 2-year period. In addition, functional single nucleotide polymorphisms in the transcriptional regulatory region of the resistin gene were examined. Results: We found no changes in the mental state of the participants over a 2-year period. Patients did show a significant decrease in total cholesterol and hemoglobin A1c levels, although physical changes such as body mass index and abdominal girth, were not observed. The amount of resistin may not be associated with mental states and physical parameters. Conclusions: We could not find physical factors related to metabolic changes of antipsychotics in this 2-year study. However, several psychological factors, such as health-related thoughts and behaviors, should be studied in the future.

show abstract

Section: Discussionsupporting

confidence: 50%

Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics

Kawabe

Ochi

Yoshino

et al. 2015

Therapeutic Advances in Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…The pattern of this association was not always clear and depends on the level of age clusters studied by researchers. Some studies though revealed a peak of MetS rates in the third, fourth or fifth decade of life with subsequent decline in MetS rates in later life [Hagg et al 2006;Sugawara et al 2010]. This effect was not consistent through all studies, and it was not present in the same way in both sexes.…”

Section: Metabolic Syndrome and Agementioning

confidence: 95%

“…This effect was not consistent through all studies, and it was not present in the same way in both sexes. A single study showed that women with schizophrenia tended to reach a peak in MetS rates in the forth decade of life, while men reach a peak in the third decade [Sugawara et al 2010]. This finding could also reflect the fact that men tend to have an earlier onset of schizophrenia than women and so are exposed longer to this condition.…”

Section: Metabolic Syndrome and Agementioning

confidence: 99%

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

Papanastasiou¹

2012

Therapeutic Advances in Psychopharmacology

100

View full text Add to dashboard Cite

Metabolic syndrome: introduction The metabolic syndrome (MetS, also known as syndrome X, syndrome of chronic cardiovascular disease and Reaven's syndrome) is a constellation of different conditions, including abdominal obesity, insulin resistance, dyslipidaemia and elevated blood pressure. All components of the MetS (with obesity holding a central role in its development) have been recognized as independent risk factors for cardiovascular disease and so the presence of MetS is associated with other comorbidities such as the prothrombotic state, proinflammatory state, nonalcoholic fatty liver disease and reproductive disorders [Cornier et al. 2008]. Owing to its multiple components, many definitions have

show abstract

“…Several studies did not find gender differences between schizophrenia patients with or without MetS (1,14,16,19,27,28,32,33). However, there are other studies which reported increased MetS prevalence in women (17,24,25,(28)(29)(30)35) or men (26).…”

Section: Introductionmentioning

confidence: 99%

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

Sarısoy¹,

Böke²,

Öztürk³

et al. 2013

Dusunen Adam

View full text Add to dashboard Cite

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patientsObjective: The purpose of this study was to determine the frequency of metabolic syndrome (MetS) in schizophrenia patients who are receiving treatment with antipsychotic drugs and also the sociodemographic and clinical characteristics of schizophrenia patients with MetS.Methods: 111 schizophrenia patients diagnosed on the basis of DSM-IV diagnostic criteria and receiving antipsychotic therapy for at least 3 months were included in the study. MetS was diagnosed on the basis of International Diabetes Fedaration (IDF) diagnostic criteria. Schizophrenia patient groups with and without diagnosed MetS were compared in terms of sociodemographic and clinical characteristics.Results: MetS was determined in 27% of the patients. The most commonly determined parameter was elevated waist circumference (65.8%). The least common parameter was elevated blood pressure (10.8%).The waist circumference parameter in women and the blood pressure parameter in men were more frequently determined. No difference was determined between schizophrenia patients with or without MetS in terms of sociodemographic characteristics, schizophrenia subtypes and symptoms or other clinical characteristics. Conclusion:MetS is a significant problem in schizophrenia patients receiving antipsychotic therapy. Elevated waist circumference is an important parameter in monitoring. The findings in the literature regarding the relationship between MetS and sociodemographic and clinical characteristics are contradictory. No correlation was determined in our study. Further studies are now needed to shed light on this subject. There would seem to be no correlation between MetS and schizophrenia subtypes and symptoms.

show abstract

Prevalence of metabolic syndrome among patients with schizophrenia in Japan

Cited by 76 publications

References 38 publications

Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics

Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics

The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review

The correlation between incidence of metabolic syndrome and sociodemographic and clinical characteristics in schizophrenia patients

Contact Info

Product

Resources

About